Skip to main content
Equibles
NUTX logo

NUTX · Nutex Health Inc. · Metrics

Track NUTX — free

Use NUTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NUTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$212.63 +4.38 (+2.10%) At close · Oct 28 Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.43B
Shares
6.85M
Volume · Oct 28 120.2K Avg daily vol (3M) 155.64K

NUTX metrics

105 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$212.63
Market cap
$1.43B

Price action

20 metrics
Price change (1W)
+4.7%
Price change (30D)
-2.1%
Price change (3M)
+39.7%
Price change (6M)
+80.9%
Price change (YTD)
+26.5%
Price change (1Y)
+60.8%
Trailing year
Price change (5Y)
—
52-week high
$225.00
52-week low
$87.01
Change from 52-week high
-7.4%
Change from 52-week low
+139.3%
Annualized volatility
89.4%
Annualized volatility (3M)
73.2%
Beta
1.7
RSI (14D)
53.6
Price vs SMA 50
+3.0%
Price vs SMA 200
+38.9%
Avg volume (3M)
155,634
Relative volume
0.8
Average dollar volume
$30.20M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
6.85M

Valuation

12 metrics
P / E (TTM)
8.0
Trailing earnings · reciprocal yield 12.5%
PEG ratio
1.0
EV / revenue
1.5×
reciprocal yield 66.9%
EV / EBITDA
3.3×
reciprocal yield 30.4%
EV / EBIT
3.5×
reciprocal yield 28.8%
P / sales
1.7×
reciprocal yield 59.2%
P / book
3.6
reciprocal yield 27.6%
FCF yield
19.2%
TTM · current market cap
Buyback yield
3.9%
P / FCF
5.2
reciprocal yield 19.2%
P / operating cash flow
5.1
reciprocal yield 19.5%
Earnings yield
10.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.7×
reciprocal yield 150.6%
EV / revenue historical average (5Y)
9.0×
reciprocal yield 11.1%
EV / EBIT historical average (3Y)
2.4×
reciprocal yield 42.1%
EV / EBIT historical average (5Y)
2.4×
reciprocal yield 42.1%
EV / EBITDA historical average (3Y)
7.8×
reciprocal yield 12.8%
EV / EBITDA historical average (5Y)
7.8×
reciprocal yield 12.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-07

Profitability

9 metrics
Gross margin
51.3%
Operating margin
43.0%
Trailing 12 months
Net margin
17.8%
Gross profit (TTM)
$434.03M
Operating profit (TTM)
$364.27M
Net income (TTM)
$150.33M
Trailing 12 months
Diluted EPS (TTM)
$26.00
FCF margin
32.4%
Effective tax rate
20.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$118.02
Gross profit per diluted share (TTM)
$60.72
Operating profit per diluted share (TTM)
$51.00
EBITDA per diluted share (TTM)
$53.93
Net income per diluted share (TTM)
$21.22
Operating cash flow per diluted share (TTM)
$38.79
Free cash flow per diluted share (TTM)
$38.02
Capital expenditures per diluted share (TTM)
$0.76
R&D per diluted share (TTM)
$2.19
Stock compensation per diluted share (TTM)
—
Book value per share
$46.49

Growth

11 metrics
Revenue growth YoY
-13.6%
Year over year
Net income growth YoY
+35.9%
Revenue (TTM)
$846.72M
Trailing 12 months
EPS growth YoY
+8.2%
Shares change YoY
+17.1%
Year over year · more shares
Revenue CAGR (3Y)
+58.6%
Revenue CAGR (5Y)
+26.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-17.2%
FCF CAGR (3Y)
+89.7%
FCF CAGR (5Y)
+57.3%

Quality

14 metrics
Return on equity
38.1%
Return on assets
15.6%
Debt / equity
0.1
Current ratio
5.0
EBITDA (TTM)
$385.27M
Free cash flow (TTM)
$274.17M
Quick ratio
5.0
Interest coverage
18.4
Net debt / EBITDA
-0.4
Return on invested capital
126.4%
Trailing 12 months
Net cash
$165.61M
Latest balance sheet
Cash & equivalents
$205.21M
Total assets
$964.63M
Total debt
$39.60M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$279.62M
Capital expenditures (TTM)
$5.45M
R&D (TTM)
$282,910
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
153
13F filer change QoQ
+23
Institutional ownership
42.9%
Conviction holders (share of 13F filers)
1.3%
Crowding (high-turnover and private-fund holders)
13.4%
Private-fund adviser ownership
11.8%
Active holders' share change QoQ
+4.0%
Holder tenure
5.8
Price vs estimated holder cost
+51.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.9%

Short interest

3 metrics
Short interest
18.1%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
83 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$43,493
Insider-sentiment score
54 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1479681 CUSIP 67079U306 13F (30d) 22 filings 22 filers Visit website Investor relations